Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Vopr Virusol ; 66(4): 241-251, 2021 09 16.
Artigo em Inglês, Russo | MEDLINE | ID: mdl-34545716

RESUMO

COVID-19 has killed more than 4 million people to date and is the most significant global health problem. The first recorded case of COVID-19 had been noted in Wuhan, China in December 2019, and already on March 11, 2020, World Health Organization declared a pandemic due to the rapid spread of this infection. In addition to the damage to the respiratory system, SARS-CoV-2 is capable of causing severe complications that can affect almost all organ systems. Due to the insufficient effectiveness of the COVID-19 therapy, there is an urgent need to develop effective specific medicines. Among the known approaches to the creation of antiviral drugs, a very promising direction is the development of drugs whose action is mediated by the mechanism of RNA interference (RNAi). A small interfering RNA (siRNA) molecule suppresses the expression of a target gene in this regulatory pathway. The phenomenon of RNAi makes it possible to quickly create a whole series of highly effective antiviral drugs, if the matrix RNA (mRNA) sequence of the target viral protein is known. This review examines the possibility of clinical application of siRNAs aimed at suppressing reproduction of the SARS-CoV-2, taking into account the experience of similar studies using SARS-CoV and MERS-CoV infection models. It is important to remember that the effectiveness of siRNA molecules targeting viral genes may decrease due to the formation of viral resistance. In this regard, the design of siRNAs targeting the cellular factors necessary for the reproduction of SARS-CoV-2 deserves special attention.


Assuntos
Antivirais/uso terapêutico , Tratamento Farmacológico da COVID-19 , Interferência de RNA , RNA Interferente Pequeno/uso terapêutico , SARS-CoV-2 , Animais , COVID-19/genética , COVID-19/metabolismo , Modelos Animais de Doenças , SARS-CoV-2/genética , SARS-CoV-2/metabolismo
2.
Zh Mikrobiol Epidemiol Immunobiol ; (5): 69-72, 1985 May.
Artigo em Russo | MEDLINE | ID: mdl-4036412

RESUMO

The avidity characteristics of salivary and serum antibodies have been determined in 179 salmonellosis patients by means of the indirect hemagglutination inhibition test. These investigation have shown that, in contrast to serum antibodies, no changes occur in the avidity of salivary antibodies in the course of the disease. This is due to the fact that secretory antibodies belong to IgA which have no tendency to ripening. The regularities thus established reflect the role of secretory and serum antibodies in the pathogenesis of Salmonella infections.


Assuntos
Anticorpos Antibacterianos/análise , Afinidade de Anticorpos , Saliva/imunologia , Intoxicação Alimentar por Salmonella/imunologia , Salmonella/imunologia , Testes de Inibição da Hemaglutinação , Testes de Hemaglutinação , Humanos , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA